Literature DB >> 31641249

Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.

Mohammed Eslam1, Jacob George2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) affects around a quarter of the global population, paralleling worldwide increases in obesity and metabolic syndrome. NAFLD arises in the context of systemic metabolic dysfunction that concomitantly amplifies the risk of cardiovascular disease and diabetes. These interrelated conditions have long been recognized to have a heritable component, and advances using unbiased association studies followed by functional characterization have created a paradigm for unravelling the genetic architecture of these conditions. A novel perspective is to characterize the shared genetic basis of NAFLD and other related disorders. This information on shared genetic risks and their biological overlap should in future enable the development of precision medicine approaches through better patient stratification, and enable the identification of preventive and therapeutic strategies. In this Review, we discuss current knowledge of the genetic basis of NAFLD and of possible pleiotropy between NAFLD and other liver diseases as well as other related metabolic disorders. We also discuss evidence of causality in NAFLD and other related diseases and the translational significance of such evidence, and future challenges from the study of genetic pleiotropy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31641249     DOI: 10.1038/s41575-019-0212-0

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  151 in total

1.  Fatty liver disease: the hepatic manifestation of metabolic syndrome.

Authors:  Amalia Gastaldelli
Journal:  Hypertens Res       Date:  2010-05-07       Impact factor: 3.872

2.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Authors:  Chris Estes; Quentin M Anstee; Maria Teresa Arias-Loste; Heike Bantel; Stefano Bellentani; Joan Caballeria; Massimo Colombo; Antonio Craxi; Javier Crespo; Christopher P Day; Yuichiro Eguchi; Andreas Geier; Loreta A Kondili; Daniela C Kroy; Jeffrey V Lazarus; Rohit Loomba; Michael P Manns; Giulio Marchesini; Atsushi Nakajima; Francesco Negro; Salvatore Petta; Vlad Ratziu; Manuel Romero-Gomez; Arun Sanyal; Jörn M Schattenberg; Frank Tacke; Junko Tanaka; Christian Trautwein; Lai Wei; Stefan Zeuzem; Homie Razavi
Journal:  J Hepatol       Date:  2018-06-08       Impact factor: 25.083

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

4.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Authors:  Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

Review 5.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

6.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

7.  The liver.

Authors:  Elijah Trefts; Maureen Gannon; David H Wasserman
Journal:  Curr Biol       Date:  2017-11-06       Impact factor: 10.834

Review 8.  Fatty liver: a novel component of the metabolic syndrome.

Authors:  Anna Kotronen; Hannele Yki-Järvinen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-09       Impact factor: 8.311

Review 9.  Mechanisms of NAFLD development and therapeutic strategies.

Authors:  Scott L Friedman; Brent A Neuschwander-Tetri; Mary Rinella; Arun J Sanyal
Journal:  Nat Med       Date:  2018-07-02       Impact factor: 53.440

10.  Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants.

Authors:  Regina Guthold; Gretchen A Stevens; Leanne M Riley; Fiona C Bull
Journal:  Lancet Glob Health       Date:  2018-09-04       Impact factor: 26.763

View more
  50 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

2.  Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.

Authors:  Bisma Rauff; Ali Amar; Shafiq Ahmad Chudhary; Saqib Mahmood; Ghias Un Nabi Tayyab; Rumeza Hanif
Journal:  Arch Virol       Date:  2021-02-02       Impact factor: 2.574

3.  The metabolic profiles and body composition of lean metabolic associated fatty liver disease.

Authors:  Yu-Ming Cheng; Jia-Horng Kao; Chia-Chi Wang
Journal:  Hepatol Int       Date:  2021-02-04       Impact factor: 6.047

4.  Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.

Authors:  Chen Ding; Yaxin Tang; Wenqiang Zhu; Piaopiao Huang; Pingan Lian; Juanli Ran; Xiansheng Huang
Journal:  Acta Diabetol       Date:  2022-01-06       Impact factor: 4.280

5.  What's new in non-alcoholic fatty liver disease?

Authors:  Jessica Spiers; James Hallimond Brindley; Wenhao Li; William Alazawi
Journal:  Frontline Gastroenterol       Date:  2022-05-31

Review 6.  The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.

Authors:  Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-10       Impact factor: 46.802

7.  Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.

Authors:  Eduardo Vilar-Gomez; Samer Gawrieh; Tiebing Liang; Adam D McIntyre; Robert A Hegele; Naga Chalasani
Journal:  J Clin Lipidol       Date:  2020-12-27       Impact factor: 4.766

8.  Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.

Authors:  Wen-Yue Liu; Mohammed Eslam; Kenneth I Zheng; Hong-Lei Ma; Rafael S Rios; Min-Zhi Lv; Gang Li; Liang-Jie Tang; Pei-Wu Zhu; Xiao-Dong Wang; Christopher D Byrne; Giovanni Targher; Jacob George; Ming-Hua Zheng
Journal:  J Clin Transl Hepatol       Date:  2021-02-22

9.  Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus.

Authors:  Ali Bayoumi; Asmaa Elsayed; Shuanglin Han; Salvatore Petta; Leon A Adams; Rocio Aller; Anis Khan; Carmelo García-Monzón; María Teresa Arias-Loste; Luca Miele; Olivier Latchoumanin; Shafi Alenizi; Rocio Gallego-Durán; Janett Fischer; Thomas Berg; Antonio Craxì; Mayada Metwally; Liang Qiao; Christopher Liddle; Hannele Yki-Järvinen; Elisabetta Bugianesi; Manuel Romero-Gomez; Jacob George; Mohammed Eslam
Journal:  Adv Sci (Weinh)       Date:  2021-05-01       Impact factor: 16.806

Review 10.  Advancing drug discovery using the power of the human genome.

Authors:  Karl Heilbron; Sahar V Mozaffari; Vladimir Vacic; Peng Yue; Wei Wang; Jingchunzi Shi; Adrian M Jubb; Steven J Pitts; Xin Wang
Journal:  J Pathol       Date:  2021-04-09       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.